Display options
Cite
Liu G, Xiong D, Zeng J, et al. Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression in gastric cancer: a systematic review and meta-analysis. Onco Targets Ther. 2017;10:4321-4328doi: 10.2147/OTT.S143089.
Liu, G., Xiong, D., Zeng, J., Chen, B., & Huang, Z. (2017). Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression in gastric cancer: a systematic review and meta-analysis. OncoTargets and therapy, 104321-4328. https://doi.org/10.2147/OTT.S143089
Liu, Gang, et al. "Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression in gastric cancer: a systematic review and meta-analysis." OncoTargets and therapy vol. 10 (2017): 4321-4328. doi: https://doi.org/10.2147/OTT.S143089
Liu G, Xiong D, Zeng J, Chen B, Huang Z. Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression in gastric cancer: a systematic review and meta-analysis. Onco Targets Ther. 2017 Sep 01;10:4321-4328. doi: 10.2147/OTT.S143089. eCollection 2017. PMID: 28919781; PMCID: PMC5590776.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2017 Sep 01;10:4321-4328. doi: 10.2147/OTT.S143089. eCollection 2017.

Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression in gastric cancer: a systematic review and meta-analysis.

OncoTargets and therapy

Gang Liu, Disheng Xiong, Junjie Zeng, Borong Chen, Zhengjie Huang

Affiliations

  1. Department of Gastrointestinal Surgery, Xiamen Cancer Hospital of the First Affiliated Hospital of Xiamen University, Xiamen.
  2. Department of Gastrointestinal Surgery, The First Clinical Medical College of Fujian Medical University, Fuzhou, People's Republic of China.

PMID: 28919781 PMCID: PMC5590776 DOI: 10.2147/OTT.S143089

Abstract

The prognostic significance of Ki-67 in patients with gastric cancer (GC) remains controversial. The aim of our meta-analysis is to evaluate its association with clinicopathological characteristics and prognostic value in patients with GC. PubMed, EMBASE, and Web of Science were systematically searched up to May 2017. Twenty-two studies including 3,825 patients with GC were analyzed. The meta-analysis indicated that the incidence difference of Ki-67 expression in GC patients was significant when comparing the older group to younger group (odds ratio [OR] =1.44, 95% confidence interval [CI] 1.19, 1.75), lymph node positive group to negative group (OR =1.49, 95% CI 1.20, 1.84), the large size tumor group to the small size tumor group (OR =1.27, 95% CI 1.24, 1.68) and the TNM stage III+IV group to TNM stage I+II group (OR =2.28, 95% CI 1.66, 3.12). However, no statistical differences existed in gender. The detection of Ki-67 significantly correlated with the overall survival of patients (hazard ratio =1.51, 95% CI 1.31, 1.72). Our study suggested that Ki-67 overexpression was associated with poor prognosis in GC patients. Ki-67 positive rates may be associated with age, lymph node metastasis, tumor size, and TNM staging system in GC patients.

Keywords: Ki-67; gastric cancer; meta-analysis; prognostic

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

  1. J Nucl Med. 2014 Feb;55(2):183-90 - PubMed
  2. J Korean Med Sci. 2006 Oct;21(5):871-6 - PubMed
  3. Tumori. 2008 Jul-Aug;94(4):531-8 - PubMed
  4. Clin Lab. 2016;62(1-2):141-53 - PubMed
  5. Gastroenterol Clin North Am. 2013 Jun;42(2):219-40 - PubMed
  6. Acta Histochem. 2014 Oct;116(8):1244-50 - PubMed
  7. Korean J Pathol. 2013 Jun;47(3):219-26 - PubMed
  8. Contemp Oncol (Pozn). 2016;20(4):311-9 - PubMed
  9. BMC Cancer. 2010 May 20;10 :218 - PubMed
  10. Oncol Lett. 2013 Nov;6(5):1277-1284 - PubMed
  11. Pathophysiology. 2017 Jun;24(2):99-106 - PubMed
  12. PLoS One. 2015 Oct 21;10(10):e0140451 - PubMed
  13. Hum Genet. 1989 Oct;83(3):297-9 - PubMed
  14. Oncotarget. 2017 Jul 4;8(27):43838-43852 - PubMed
  15. Folia Histochem Cytobiol. 2009;47(2):289-96 - PubMed
  16. J Cell Physiol. 2000 Mar;182(3):311-22 - PubMed
  17. Int J Clin Exp Pathol. 2015 Jun 01;8(6):7287-90 - PubMed
  18. Cell Prolif. 2007 Jun;40(3):422-30 - PubMed
  19. J Cell Physiol. 2006 Mar;206(3):624-35 - PubMed
  20. N Engl J Med. 2006 Jul 6;355(1):76-7 - PubMed
  21. Anticancer Res. 2009 Feb;29(2):703-9 - PubMed
  22. Med Oncol. 2015 Jan;32(1):433 - PubMed
  23. Oncol Rep. 1998 Jul-Aug;5(4):867-70 - PubMed
  24. Tumour Biol. 2014 Aug;35(8):7505-12 - PubMed
  25. Tumour Biol. 2016 Jan;37(1):661-72 - PubMed
  26. Eur J Surg Oncol. 2013 Feb;39(2):141-9 - PubMed
  27. Tumour Biol. 2012 Oct;33(5):1557-63 - PubMed
  28. J Surg Oncol. 2010 Sep 1;102(3):201-6 - PubMed
  29. Exp Mol Pathol. 2016 Jun;100(3):514-21 - PubMed

Publication Types